Special Populations: Treatment-Resistant Depression in Children and Adolescents.

Major depressive disorder is a substantial public health challenge impacting at least 3 million adolescents annually in the United States. Depressive symptoms do not improve in approximately 30% of adolescents who receive evidence-based treatments. Treatment-resistant depression in adolescents is broadly defined as a depressive disorder that does not respond to a 2-month course of an antidepressant medication at a dose equivalent of 40 mg of fluoxetine daily or 8 to 16 sessions of a cognitive behavioral or interpersonal therapy. This article reviews historical work, recent literature on classification, current evidence-based approaches, and emerging interventional research.

• Publication year

  2023

• Venue

  Psychiatric Clinics of North America

• Publication date

  2023-03-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/j.psc.2023.02.007PMID 37149350
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Long-Term Effects of Lithium Use on Children and Adolescents: A Retrospective Study from Turkey

  2022cited by this paper
• Vortioxetine for Major Depressive Disorder in Adolescents: 12-Week Randomized, Placebo-Controlled, Fluoxetine-Referenced, Fixed-Dose Study.

  2022cited by this paper
• Systematic review: Electroconvulsive therapy for treatment-resistant mood disorders in children and adolescents

  2022cited by this paper
• Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression

  2022cited by this paper
• Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.

  2022cited by this paper
• A Systematic Review of the Safety and Tolerability of Theta Burst Stimulation in Children and Adolescents

  2021cited by this paper
• Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis.

  2020cited by this paper
• A Randomized, Double-Blind, Placebo-Controlled Trial of Vilazodone in Children and Adolescents with Major Depressive Disorder with Twenty-Six-Week Open-Label Follow-Up

  2020cited by this paper
• Left prefrontal transcranial magnetic stimulation for treatment-resistant depression in adolescents: a double-blind, randomized, sham-controlled trial

  2020cited by this paper
• Annual Research Review: Defining and treating pediatric treatment-resistant depression.

  2020cited by this paper
• Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder

  2017cited by this paper
• Desvenlafaxine Versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder

  2017cited by this paper
• Comorbid Anxiety and Depressive Symptoms in Children and Adolescents: A Systematic Review and Analysis

  2016cited by this paper
• The Dutch Measure for quantification of Treatment Resistance in Depression (DM-TRD): an extension of the Maudsley Staging Method.

  2016cited by this paper
• A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression.

  2016cited by this paper
• Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.

  2016cited by this paper
• Continued Effectiveness of Relapse Prevention Cognitive-Behavioral Therapy Following Fluoxetine Treatment in Youth With Major Depressive Disorder.

  2015cited by this paper
• Comparative efficacy and acceptability of psychotherapies for depression in children and adolescents: A systematic review and network meta‐analysis

  2015cited by this paper
• Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence

  2015cited by this paper
• Major depression in the national comorbidity survey-adolescent supplement: prevalence, correlates, and treatment.

  2015cited by this paper
• A Double-Blind, Placebo-Controlled Study of Selegiline Transdermal System in Depressed Adolescents

  2014cited by this paper
• A Double-Blind Efficacy and Safety Study of Duloxetine Fixed Doses in Children and Adolescents with Major Depressive Disorder

  2014cited by this paper
• Safety and Tolerability of Desvenlafaxine in Children and Adolescents with Major Depressive Disorder

  2014cited by this paper
• Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.

  2013cited by this paper
• Tricyclic drugs for depression in children and adolescents.

  2013cited by this paper
• Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatment-resistant depression.

  2012cited by this paper
• Clinical expression of bipolar disorder type I as a function of age and polarity at onset: convergent findings in samples from France and the United States.

  2012cited by this paper
• Do sub-syndromal manic symptoms influence outcome in treatment resistant depression in adolescents? A latent class analysis from the TORDIA study.

  2012cited by this paper
• Antipsychotic Treatment Among Youth in Foster Care

  2011cited by this paper
• Factors Associated with Antidepressant Adherence for Medicaid-Enrolled Children and Adolescents

  2011cited by this paper
• IPT and PTSD

  2010cited by this paper
• Treatment of Resistant Depression in Adolescents (TORDIA): week 24 outcomes.

  2010cited by this paper
• Risk factors of treatment resistance in major depression: association with bipolarity.

  2010cited by this paper
• Predictors of efficacy in lithium augmentation for treatment-resistant depression.

  2010cited by this paper
• A multidimensional tool to quantify treatment resistance in depression: the Maudsley staging method.

  2009cited by this paper
• An Exploratory Analysis of the Impact of Family Functioning on Treatment for Depression in Adolescents

  2009cited by this paper
• Substance use and the treatment of resistant depression in adolescents.

  2009cited by this paper
• Treated depression in adolescents: predictors of outcome at 28 weeks.

  2009cited by this paper
• Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials.

  2009cited by this paper
• Early prediction of acute antidepressant treatment response and remission in pediatric major depressive disorder.

  2009cited by this paper
• Individual and group CBT and IPT for Puerto Rican adolescents with depressive symptoms.

  2008cited by this paper
• A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial.

  2008cited by this paper
• Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.

  2008cited by this paper
• Prevalence and management of treatment-resistant depression.

  2007cited by this paper
• Texas Children's Medication Algorithm Project: update from Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder.

  2007cited by this paper
• The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes.

  2007cited by this paper
• Practice parameter for the assessment and treatment of children and adolescents with depressive disorders.

  2007cited by this paper
• Predictors and moderators of acute outcome in the Treatment for Adolescents with Depression Study (TADS).

  2006cited by this paper
• Paroxetine treatment in children and adolescents with major depressive disorder: a randomized, multicenter, double-blind, placebo-controlled trial.

  2006cited by this paper
• Fluoxetine 40–60 mg versus Fluoxetine 20 mg in the Treatment of Children and Adolescents with a Less-Than-Complete Response to Nine-Week Treatment with Fluoxetine 10–20 mg: APilot Study

  2006cited by this paper
• Interpersonal Psychotherapy for depressed adolescents (IPT-A): An overview

  2006cited by this paper
• A closer look at treatment resistant depression: is it due to a bipolar diathesis?

  2005cited by this paper
• Long-term implications of early onset in bipolar disorder: data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD).

  2004cited by this paper
• Diagnosis and definition of treatment-resistant depression.

  2003cited by this paper
• A Combined Cognitive–Behavioral Family Education Intervention for Depression in Children: A Treatment Development Study

  2002cited by this paper
• The definition and meaning of treatment-resistant depression.

  2001cited by this paper
• Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial.

  2001cited by this paper
• Treatment resistant depression: methodological overview and operational criteria.

  1999cited by this paper
• Lithium Augmentation of Venlafaxine in Adolescent Major Depression

  1998cited by this paper
• When at first you don't succeed: sequential strategies for antidepressant nonresponders.

  1997cited by this paper
• Definition and epidemiology of treatment-resistant depression.

  1996cited by this paper
• Major depression in community adolescents: age at onset, episode duration, and time to recurrence.

  1994cited by this paper
• Lithium antidepressant augmentation in TCA-refractory depression in adolescents.

  1988cited by this paper

• Prevalence, severity, and risk factors for depressive and anxiety symptoms among adolescents: A cross-sectional study

  2026cites this paper
• Contemporary adolescent depression: Multidimensional analysis from neurobiological, psychological, and social integrative perspectives

  2026cites this paper
• Sequenced treatment alternatives to relieve adolescent depression: A pragmatic clinical trial.

  2026cites this paper
• A naturalistic analysis of rTMS treatment outcomes for major depressive disorder in West Australian youth

  2025cites this paper
• Effects of Lutjanus erythropterus Protein on Depression-like Behavior and Gut Microbiota in Stressed Juvenile Mice

  2025cites this paper
• A feasibility study of sequenced TMS and TBS dosing in adolescents with major depressive disorder

  2025cites this paper
• Making Progress in Psychopharmacology for Challenges in Treating Depression in Youth

  2025cites this paper
• Major challenges in youth psychopathology: treatment-resistant depression. A narrative review

  2024cites this paper
• Clinical outcomes in adolescents undergoing sequential bilateral 1 Hz/20 Hz transcranial magnetic stimulation for treatment resistant depression.

  2024cites this paper
• Effects of Ketamine vs. Midazolam in Adolescent Treatment Resistant Depression

  2024cites this paper
• Interventional approaches to treatment resistant depression (DTR) in children and adolescents: A systematic review and meta-analysis.

  2024cites this paper
• Novel rapid treatment options for adolescent depression.

  2024cites this paper